The mission of the NRG Oncology Statistics and Data Management Center (SDMC) is to provide all necessary expertise and personnel for the design, conduct and analysis of clinical trials and associated research for NRG Oncology, a member group of the NCI National Clinical Trials Network (NCTN) program. The Administrative Core provides the components of the SDMC critical to a) leadership within the SDMC overall and between Core components, b) coordination with NRG Oncology Operations to effectively provide to the group necessary support for the research agenda and for investigators, including vital functions such as data and trial quality assurance and c) coordination with other Network groups and with the NCI to collectively meet the goals of the NCTN. The 2019-2024 cycle represents the second period of the NCTN program, which succeeded the NCI Cancer Cooperative Group program, of which NRG Oncology was formed by the unification of three existing Cooperative Groups. The re-organization to provide a structure that capitalizes on a wealth of skills and experience while avoiding inefficiencies was a challenge successfully met in the first cycle. The current leadership structure provides seamless work among sites under common procedures, with divisions organized by function rather than geography, while continuing to take advantage of longstanding expertise that may reside in a specific office (and thus are not redundant). Success during the first cycle is evidence by over 45 new trials either initiated or currently approved and in development, while accrual and/or follow-up to primary and secondary endpoint reporting on over 80 additional trials that were active at the inception of NRG Oncology. The NRG Oncology trials accruing during 2014-2017 represent 34% of all accruing NCTN trials. Publications from the group in the first cycle number well over 300, including 39 methodology articles by SDMC statisticians. The administrative structure of the SDMC has allowed it to serve as a highly functioning productive resource for NRG Oncology and the NCTN. In the second cycle of the NCTN, the Administrative Core will continue to enhance the integration of the group towards a seamless unit that serves all the operational needs of the SDMC as it carries out its mission. Specifically, the Administrative Core will provide the governance, strategic planning, scientific direction, logistical oversight, administrative resources and decision-making for the NRG Oncology Statistics and Data Management Center. The Core will lead critical liaisons with the NRG Operations Center, NCTN member groups, the NCI, pharmaceutical companies, and the FDA to ensure that research goals are met. The Core will provide quality assurance oversight to the other SDMC sections and to the NRG investigative sites, ensuring the integrity of the database and trial findings. Finally, the core will provide administrative resources and training to SDMC staff through adherence to its library of Standard Operating Procedures (SOPs).!

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180822-07
Application #
9901458
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Tew, William P; Sill, Michael W; Walker, Joan L et al. (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:257-263
Timmerman, Robert D; Paulus, Rebecca; Pass, Harvey I et al. (2018) Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol 4:1263-1266
Richardson, Debra L; Sill, Michael W; Coleman, Robert L et al. (2018) Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4:196-202
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162
Wapnir, Irene L; Price, Karen N; Anderson, Stewart J et al. (2018) Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 36:1073-1079
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Valicenti, Richard K; Pugh, Stephanie L; Trabulsi, Edouard J et al. (2018) First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys 100:695-701
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180

Showing the most recent 10 out of 331 publications